HP
MDGL icon

HealthInvest Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

HealthInvest Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,539
Closed -$945K – 45
2024
Q1 		$945K Buy
3,539
+1,008
+40% +$238K 0.58% 38
2023
Q4 		$586K Buy
+2,531
New +$443K 0.46% 40

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HealthInvest Partners's MDGL Position: Q2 2024 in Review

HealthInvest Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 3,539 shares — an estimated $945K sold.

HealthInvest Partners first reported a position in MDGL in Q4 2023 and held it in 2 quarters. The position peaked at $945K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • HealthInvest Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • HealthInvest Partners sold 3,539 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $945K.
  • HealthInvest Partners first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • HealthInvest Partners's Madrigal Pharmaceuticals position peaked at $945K in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on HealthInvest Partners's 13F filing for Q2 2024, filed 14 Aug 2024.